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ABSTRACT:
Ten p-nitrodiarylthiourea analogs were designed, synthesized and evaluated in breast (MCF-7, T47D, MDA-MB-453) and prostate (DU-145, PC-3, LNCaP) cancer cell lines for their anticancer
activities. Majority of the compounds were able to inhibit the growth of these six cancer cell lines at
low micromolar concentrations. Compound 7 was found to be the most potent anticancer agent in
this series with GI50 values of 3.16 M for MCF-7, 2.53 M for T-47D, 4.77 M for MDA-MB-453
breast cancer lines and 3.54 M for LNCaP prostate cancer cell line. These G150 values were
comparable to the original parent compound, SHetA2.
GRAPHICAL ABSTRACT:

ABBREVIATIONS:
SHetA2: N-(2,3-dihydro-2,2,4,4-tetramethyl-6-benzothiopyranyl), N’-(4-nitrophenyl)thiourea;
ATRA: all trans retinoic acid; NOAEL: no observed adverse effect level; MTT: 3-(4,5Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide; MTS: MTT coupled with phenazine
methosulfate (soluble form of MTT) ; ER: estrogen receptor; AR: androgen receptor

Previously, we synthesized N-(2,3-dihydro-2,2,4,4-tetramethyl-6-benzothiopyranyl), N’-(4nitrophenyl)thiourea (SHetA2, NSC 726189)1 which has been shown to be a novel potential cancer
prevention agent and is now in preclinical development for cancer prevention and treatment through
the National Cancer Institute (NCI) Rapid Access to Intervention Development (RAID) program.
The studies of SHetA2 were reviewed extensively.2,3 SHetA2 was evolved from a lead optimization

process from all trans-retinoid acid (ATRA, Tretinoin®, Mean GI50 51 M, Figure 1),2,3,4 which is
used for the treatment of acute promyelocytic leukemia. However, the exploitation of retinoic acid’s
full potential as chemopreventive and/or therapeutic drugs, particularly against solid tumors, has
been hampered mainly by their local and systemic toxicity and side effects, which are often
associated with their ability to activate nuclear retinoid receptors.2 Thus, efforts have been made to
develop novel compounds that retain retinoid anticancer activity with minimal retinoid toxicity and
side effects. SHetA2 is such a compound, a more effective anticancer agent than ATRA and appears
to function without activating retinoid receptors.1 As a result, it has been shown to lack retinoid
toxicities when tested in animal models.3 SHetA2 exerts its selective anticancer activity through
regulating apoptosis, cell growth, differentiation and angiogenesis.5,6 SHetA2 has been shown to
induce proteasomal degradation of cyclin D1,7 generate mitochondrial swelling and endoplasmic
reticulum stress, promote the formation of reactive oxygen species, and induce apoptosis in cancer
cells while sparing normal cells.6 More importantly, it was reported recently in a dog study, that no
toxicity of SHetA2 was observed in any tested dose groups. The lowest observed adverse effect
level (NOAEL) for ShetA2 was not established and was considered to be above 1,500 mg/kg/day.8
However, SHetA2 may not be an ideal drug candidate due to the following two limitations:
its high lipophilicity and cumbersome six step synthesis 1) Its high lipophilicity (LogP 7.09, higher
than the upper limit of “Lipinski rule of 5” and the Log P of most marketed drugs),9,10 might
contribute to its extremely low (<1%) systemic bioavailability for all doses tested in rat and high
plasma protein binding (99.3-99.5% at low micromolar concentrations).6, 11 In addition, this high
lipophilicity might potentially cause nonselectivity, liver toxicity and drug-drug interactions.12 2)
Its synthesis involves 6 steps with low overall yield of 3%, which hinders its large scale supply and
new analog synthesis.13 To address these issues, we have modified the SHetA2 structure based on
the previous structure-activity relationship.1, 2 We hypothesized that the nitrophenyl group and the
thiourea linker in SHetA2 structure are important for its anticancer activity. Thus, our modification
strategy was to keep these two moieties intact while replacing the thiochromane ring with another
ring structure. In this way, we anticipate to reduce both the lipophilicity of the designed
compounds and simplify the six-step synthesis to one step using readily available and inexpensive
starting materials.
Here, we report the design, synthesis and biological activity of ten diarylthiourea analogs.
These compounds were synthesized according to our previously published procedure.1 The newly

synthesized compounds were evaluated for their ability to inhibit the growth of breast cancer cell
lines-MCF-7, T-47D, and MDA-MB-453 and prostate cancer cell lines-DU-145, LNCaP and PC-3.
The potency of compounds 5 and 7 in this series were shown to be comparable to the parent
compound, SHetA2.

General procedure for the preparation of compounds 1-10 with the overall yield of 19%-87% from
amines and 4-nitrophenyl isothiocyanate is shown in Scheme 1. To a solution of amines (1.0 mmol)
in dry THF (4.5 mL) at 0oC under nitrogen, 4-nitrophenyl isothiocyanate (1.02 mmol) in dry THF (5
mL) was added dropwise over 3 min. After the addition, the reaction mixture was allowed to warm
to room temperature and then was stirred overnight. The solvent was evaporated, and residue was
recrystallized or purified by flash column chromatography to give an analytically pure sample of the
corresponding thiourea product. The chemical structures of compounds 1-10 were confirmed by 1H,
C13 NMR and LC-MS. The Log P, calculated Log P and the overall yield is summarized in table 1.
Further reaction details and characterizations are provided in the Supplementary data.

Cell Culture: MCF-7, T-47D, MDA-MB-453, DU-145, PC-3 and LNCaP cells were obtained from
ATCC and cultured and maintained according to ATCC protocols. Briefly, MCF-7 and MDA-MB453 cells were maintained in Dulbeco’s minimal essential medium (DMEM) supplemented with
10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. T-47D, DU-145, LNCaP and PC-3
cells were maintained in RPMI-1640 medium supplemented with 10% FBS and 1%
penicillin/streptomycin. All cells were maintained in an incubator at 37oC, 95% relative humidity
and 5% CO2 atmosphere. Sub-culturing of all cells was done every three days. 10 mM stock
solutions of compound 1-10 were made in DMSO and stored at -20oC. Working solutions (100µM)
were made in cell culture media by serial dilution just prior to addition of the compounds in 96 well
plates.

Cell viability assay: To test the effects of the diarylthiourea analogs on breast cancer cells, two
thousand cells (MCF-7, MDA-MB-453, or T-47D) were plated in 96 well flat bottom plates.
Twenty-four hours later, cells were treated with varying concentration (0.5 µM, 1.0 µM, 5.0 µM,
10.0 µM, or 20.0µM) of either a diarylthiourea analog (1-10), ShetA2, all trans retinoic acid
(ATRA), or mock treated with the vehicle. Cytotoxicity was monitored 48 hours later by adding

20µL of MTT (Sigma). Cell viability was determined after a 2-hour incubation by dissolving the
tetrazolium crystals with DMSO and absorbances were measured at 595nm with plate reader
(Biorad, Hercules, CA). Means and standard deviations represent at least two independent
experiments done in six replicates.
The analogs were also tested on prostate cancer cells, where five thousand DU-145, PC-3
and LNCaP cells were plated in 96-well flat bottom plates for 24 hours prior to treating them with
varying concentrations (0.5 µM, 1.0 µM, 5.0 µM, 10.0 µM, or 20.0 µM) of either a diarylthiourea
analog, ShetA2, all trans retinoic acid (ATRA), or mock treated with the vehicle. Following 48hours incubation, 20µL of MTS reagent (CellTiter 96® Aqueous One Solution Reagent; Promega,
Madison, WI) was added to each well according to the manufacturer’s instructions. Cell viability
was determined after a 2-hour incubation by measuring the absorbance at 490nm using a Spectra
Max M5 plate-reader (Molecular Devices, Sunnyvale, CA). Means and standard deviations
represent at least two independent experiments done in triplicates. Cell proliferation assays were
performed in a similar manner, except cell growth was monitored for 2, 3 and 4 days after addition
of the drug with either MTT or MTS (breast cancer cell lines and prostate cancer cell lines,
respectively).
Growth inhibition 50 (GI50) is defined as the concentration at which 50% of cell-growth is
inhibited. The GI50 was calculated for each analog as follows. For each concentration value c (c =
0.5 µM, 1.0 µM, 5.0 µM, 10.0 µM, or 20.0 µM), the absorbance of the test well after a 48-hour
period of exposure was computed and averaged over all replicates to yield a mean absorbance T(c).
An exponential equation (𝐓(𝐜) = 𝐛𝟏 𝐞𝐱𝐩(𝐛𝟐 𝐜) + 𝐛 𝟑 ) was used to model the absorbance as a
function of concentration c, using non-linear least squares regression, weighted by the inverse
variance of the observations. For some analogs, the exponential model degenerated to a linear
model; weighted linear least squares regression was used instead for these analogs. GI50 was
computed as the concentration c for which (T(c) - T0)/(C - T0) = 0.5, using the exponential or linear
model to interpolate, where T0 represents absorbance at time zero and C represents vehicle control
absorbance, averaged over all replicates in the experiment. The reported means and standard
deviations of GI50 represent at least two independent experiments with either six replicates (breast
cancer cells) or triplicates (prostate cancer cells).

The preclinical studies of SHetA2 on cell culture and animal models showed that it is a
promising agent for cancer prevention and treatment without significant toxicity and side effects.6-8
However, SHetA2 is too lipophilic, with a Log P value of 7.09, which can hinder its oral
bioavailability as an anticancer drug, since optimal Log P for most oral drugs is between 1-3. We
have designed the SHetA2 analogs with Log P value between 2.99 and 6.36 (Table 1) so that all our
compounds are less lipophilic than the lead compound SHetA2 with the premise that these
compounds would have better pharmacokinetic profiles. In addition, as previously reported, the six
step synthesis of SHetA2 suffers from a low overall yield of 3% and this procedure involves use of
reagents that are toxic and have unpleasant odor.8 Tallent’s group reported a modified procedure
for the synthesis of key intermediates to the SHetA2 with improved yield, but started with much
more expensive chemicals and used column chromatography after every synthesis step.13 We have
developed a simple, one step synthesis procedure of the target compounds with cheap and
commercially available chemicals with overall yield of 19%-87% (Table 1). By far in published
literature, only certain diarylurea multi-target kinase inhibitors have chemical structures related to
our compounds.14,15 Sorafenib is among one of these compounds that have been approved for the
treatment of advanced renal cell cancer by the FDA. In addition, the wide diversity of cellular and
molecular targets that can be regulated by judiciously modifying N, N’-diarylureas and ureas,
suggests this part of the molecule may serve as privileged scaffolds for anticancer agents.14,15
The synthesized diarylthiourea analogs 1-10 were tested on three breast cancer cell lines 
MCF7, T-47D and MDA-MB-453 cells (Table 2). While majority of the compounds showed some
effect on inhibiting growth of all three breast cancer cell lines, diarylthiourea analogs 5 and 7
showed the most significant effects. The GI50 values of compounds 5 and 7 were comparable to the
parent SHetA2 (2.94-6.27 µM and 2.53-4.77 µM vs. 3.27-4.13 µM, respectively), with the T-47D
cells displaying the greatest sensitivity to these compounds when compared to MCF7 and MDAMB-453. Since compound 7 appeared to be the most effective in inhibiting the growth of all three
breast cancer cell lines, its ability to inhibit cell growth over a longer period of time was evaluated
(Figure 2 A-C). Results in figure 2 indicate that compound 7 continued to inhibit cell growth 4 days
after treatment and appeared to effectively inhibit the growth of all three breast cancer cell lines.
The diarylthiourea analogs of SHetA2 were also tested on three prostate cancer cell lines—
DU-145, PC-3 and LNCaP. Overall, LNCaP cells were more susceptible to the growth inhibitory
effects of these agents (Table 2). Compound 7 showed the most potent growth inhibitory effect in

LNCaP cells as evidenced by a low GI50 value of 3.54 µM. This value was comparable to the GI50
value (2.25 µM) of SHetA2 in the same cell-line (Table 2). Being the most potent of the
diarylthiourea analogs, compound 7 was tested for its ability to inhibit cell growth over a longer
period of time (Figure 2D). This experiment was carried out in LNCaP cells that were most
vulnerable to the growth inhibitory effects of compound 7. Cell growth was significantly inhibited
with 5 µM compound 7 staring at day 2 and remained so until day 4. Similar trend in growth
inhibition was observed at higher concentrations (10 and 20 µM) as well (Figure 2D). Moreover,
while SHetA2 inhibited the growth of all three prostate cancer cell-lines uniformly, compound 5
and 7 selectively inhibited the growth of only one of the prostate cancer cell lines, the LNCaP cells.

Here we report a simple, one step synthesis procedure to obtain a variety of diarylthiourea
derivatives of SHetA2 and their biological evaluation in human breast and prostate cancer cells. The
simple syntheses involved a coupling reaction of 4-nitropheny isothiocyanate in dry THF with
commercially available amines.. Most of them caused growth inhibition of these cancer cells.
Among them, two compounds showed potency comparable to the lead compound, SHetA2. The
study also validated our previous hypothesis that the 4-nitrophenyl group and the thiourea linker are
important for the anticancer activity of SHetA2 because all the compounds tested have these
moieties. Modification of other functional groups in SHetA2 resulted in active anticancer agents.
Therefore, this study has provided a new approach to the design and synthesis of the next generation
of novel anticancer agents, perhaps with novel mechanisms of action.
We tested the new diarylthiourea analogs along with SHetA2 on three breast cancer and
three prostate cancer cell lines and our results (Table 2) show that diarylthiourea analog 5 and 7 are
effective in inhibiting cancer cell growth of four cancer cell lines— MCF7, T-47D, MDA-MB-453
(breast cancer cells) and LNCaP (prostate cancer cell). SHetA2 was previously evaluated in the
panel of National Cancer Institute (NCI) human tumor cell lines by the Developmental Therapeutics
Program (DTP) and results showed that SHetA2 inhibited growth of most cancer cells in the
micromolar range. Specifically, reported GI50 values of 4.5 M for MCF-7, 4.8 M for T-47D, 5.0
M for MDA-MB-453, 4.9 M for DU145 and 5.0 M for PC-3,6,16 is consistent with our results
shown in Table 2. Our newly synthesized compounds (5 and 7) showed equivalent potency in
comparison to the lead compound SHetA2 (Table 2). Noteworthy are the effects of compounds 5
and 7 on the three prostate cancer cell lines. Both these agents have shown to be more selective in

inhibiting the growth of LNCaP cells in comparison to PC-3 and DU-145 cell-lines. As seen in
Table 2, compound 7 is about six times more potent in inhibiting growth of LNCaP cells than PC-3
and DU145 cells and compound 5 is at least twice as potent in LNCaP cells than in PC-3 and DU145 cells. This observation is significant since SHetA2 does not show any such selectivity (Table
2). One explanation for this selectivity could be due to differential androgen receptor signaling
patterns in the three cell lines. Both PC-3 and DU-145 cell-lines do not express androgen receptors
(AR) and are not androgen dependent for their growth, while LNCaP cells express AR (with a point
mutation in the ligand binding domain) and are considered androgen-dependent cells17. Therefore,
we hypothesize that these new analogs, compounds 5 and 7, may employ a different mechanism to
induce growth inhibition in prostate cancer cell lines as compared to SHetA2. Whether this
mechanism involves the regulation of androgen receptors (AR) requires further investigation.
However, this differential response was not as significant in the breast cancer models.
MCF7 and T-47D cells are both estrogen receptor (ER) positive (presence of ER) and are
considered hormone-dependent, whereas MDA-MB-453 is ER negative (absence of ER). While
the G150 for the ER positive cells were lower in comparison to the ER negative breast cancer cells,
the difference is not statistically significant (Table 2). The differences observed in the breast and
prostate cancer cells might be attributed to different mechanisms of action in the two cancer types.
Although MDA-MD-453 is considered ER negative breast cancer cells, similar to MCF7 and T47D, these cells do express ER.
In conclusion, this is the first report that demonstrates the growth inhibitory properties of
SHetA2 and a new generation of diarylthiourea analogs on both breast and prostate cancer cells.
While compounds 1-10 are not more potent than the SHetA2, we report for the first time the effects
of p-nitrodiarylthiourea compounds on the inhibition of both breast and prostate cancer cells, along
with a more simplified synthetic scheme. Data from this study indicate that these novel potential
anticancer agents are promising lead compounds for further evaluation. While the mechanism of
action and pharmacokinetic profile of these compounds remain to be elucidated in future studies,
results presented in this study provide a strong foundation for further preclinical studies of these
compounds as potential therapeutic agents for both breast and prostate cancers.
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Supplementary Material: The synthesis procedures and spectrum data of each compound are
provided as a separate electronic file. It can be transformed into PDF format.
FIGURE LEGENDS
Scheme 1: General procedure for the synthesis of the compound 1-10
Figure 1: Evolution of SHetA2
Figure 2: Breast cancer (A) MDA-MB-453, (B) MCF7, (C) T-47D, and prostate cancer (D) LNCaP
cells were plated in 96-plates and treated with varying concentrations of SL-01-18 for 2, 3 and 4
days. Cell growth was analyzed with MTT (A-C) or MTS (D). Means and standard deviations
represent at least two independent experiments done in six replicates.

Table 1. Some SHetA2 derivatives (1-10) produced according to Scheme 1
Compounds

Name

Log Pa

CLog Pa

Total Yield (%)

1

SL-01-03

3.83

3.51

83

2

SL-01-05

ND

5.01

19

3

SL-01-06

3.84

3.05

23

4

SL-01-08

ND

2.83

24

5

SL-01-09

4.11

4.52

87

6

SL-01-15

5.34

5.39

35

7

SL-01-18

6.36

6.08

42

8

SL-01-19

5.24

4.91

70

9

SL-01-20

3.59

3.54

60

10

SL-01-21

2.88

2.66

73

Parent

SHetA2

7.09

5.74

3

aLog

P and Clog P were calculated with ChemDraw.

Table 2. Potency (GI50 values) in M
Name and Chemical
Structure

Breast cancer cell lines (M)
Mean±SD

Prostate cancer cell lines (M)
Mean±SD

MCF-7

T-47D

MDA-MB-453

DU-145

PC-3

LNCaP

16.96 ±3.351

8.14±1.792

13.48±1.961

35.15±15.42

26.77±13.251

10.58±1.951

1
H
N

H3C

H
N

1

S

H3C

NO2

2
12.81±2.461

9.44±0.121

6.88±0.831

5.87±0.922

19.59±0.681

5.86±0.412

ND*

21.62±0.851

ND*

ND*

ND*

40.47±28.821

ND*

15.28±3.271

ND*

ND*

ND*

23.53±7.111

6.21±1.951

2.94 ±0.912

6.27±0.391

13.69±4.151

13.90±1.092

6.05±0.182

7.81±1.192

3.96 ±0.582

6.20±2.422

17.48±2.201

16.50±1.171

11.32±3.901

3.16±1.792

2.53±0.392

4.77±2.212

21.78±3.981

19.96±3.321

3.54±0.172

13.30±2.731

11.55±3.871

14.49±4.581

6.11±1.302

19.27±0.411

7.29±2.352

13.08±1.741

8.68±2.341

27.59±7.221

24.10±5.401

22.56±3.981

12.75±0.601

9.89±1.622

ND*

ND*

ND*

ND*

ND*

4.13±0.572

3.99±0.062

3.27±0.332

3.47±0.422

4.80±1.532

2.25±1.042

12.39±0.261

0.82±0.032

9.51±0.611

11.64±0.541

12.64±0.381

10.33±0.751

3
H
N
H3 C

H
N
S

N
H

NO2

SL-1-06

4
H
N

N

H
N
S

S

NO2

5
H3C

H
N

H
N
S

NO2

6

7

8

9

10

SHetA2
H
N
S

H
N
S

NO2

All Trans-RA

1

Based on linear model
Based on exponential model
* ND=Not determined or GI50 >>50μM
2

